171 related articles for article (PubMed ID: 10597732)
21. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
Sava T; Basso U; Porcaro A; Cetto GL
Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic options for hormone-refractory prostate cancer in 2007.
Hadaschik BA; Gleave ME
Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
[TBL] [Abstract][Full Text] [Related]
23. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
24. Current strategies in the treatment of metastatic hormone-refractory prostate cancer.
Ghosn M; Kattan J; Younes F
Tunis Med; 2005 Dec; 83 Suppl 12():74. PubMed ID: 16430073
[No Abstract] [Full Text] [Related]
25. Angiogenesis-targeted therapies in prostate cancer.
Lara PN; Twardowski P; Quinn DI
Clin Prostate Cancer; 2004 Dec; 3(3):165-73. PubMed ID: 15636683
[TBL] [Abstract][Full Text] [Related]
26. The role of angiogenesis inhibitors in prostate cancer.
Aragon-Ching JB; Dahut WL
Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479
[TBL] [Abstract][Full Text] [Related]
27. Novel targets and approaches in advanced prostate cancer.
Hadaschik BA; Sowery RD; Gleave ME
Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
[TBL] [Abstract][Full Text] [Related]
28. Clinical trials referral resource. Flavopiridol.
Colevas D; Blaylock B; Gravell A
Oncology (Williston Park); 2002 Sep; 16(9):1204-5, 1210-2, 1214. PubMed ID: 12380947
[No Abstract] [Full Text] [Related]
29. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
30. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma].
Song Y; Shen K; Tang PP
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):761-4. PubMed ID: 18307904
[TBL] [Abstract][Full Text] [Related]
31. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer.
Eton DT; Shevrin DH; Beaumont J; Victorson D; Cella D
Value Health; 2010 Aug; 13(5):613-23. PubMed ID: 20230544
[TBL] [Abstract][Full Text] [Related]
32. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
Shapiro GI; Supko JG; Patterson A; Lynch C; Lucca J; Zacarola PF; Muzikansky A; Wright JJ; Lynch TJ; Rollins BJ
Clin Cancer Res; 2001 Jun; 7(6):1590-9. PubMed ID: 11410495
[TBL] [Abstract][Full Text] [Related]
33. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
34. Clinical trials referral resource. Clinical trials with perillyl alcohol.
Zweibel J; Ho P; Sepelak SB; Saunders J; Cheson BD; Nelson A
Oncology (Williston Park); 1997 Dec; 11(12):1817, 1820. PubMed ID: 9436188
[No Abstract] [Full Text] [Related]
35. Newer therapies in advanced prostate cancer.
Hegeman RB; Liu G; Wilding G; McNeel DG
Clin Prostate Cancer; 2004 Dec; 3(3):150-6. PubMed ID: 15636681
[TBL] [Abstract][Full Text] [Related]
36. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches.
van Moorselaar RJ; Voest EE
Mol Cell Endocrinol; 2002 Nov; 197(1-2):239-50. PubMed ID: 12431818
[TBL] [Abstract][Full Text] [Related]
37. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
Di Lorenzo G; De Placido S
Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
[TBL] [Abstract][Full Text] [Related]
38. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
[TBL] [Abstract][Full Text] [Related]
39. Drug design strategies for the treatment of prostate cancer.
Lauer RC; Friend SC; Rietz C; Pasqualini R; Arap W
Expert Opin Drug Discov; 2015 Jan; 10(1):81-90. PubMed ID: 25366417
[TBL] [Abstract][Full Text] [Related]
40. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
Shapiro GI
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4270s-4275s. PubMed ID: 15217973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]